2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUV
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2015
Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group
Kelly K, Cole P, Chen L, Roberts K, Hodgson D, McCarten K, Cho S, Schwartz C. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. Blood 2015, 126: 3927. DOI: 10.1182/blood.v126.23.3927.3927.Peer-Reviewed Original ResearchHigh-risk Hodgkin lymphomaRapid early responseCompletion of chemotherapyABVE-PCStage IIIBOncology GroupOverall survivalPediatric patientsHodgkin's lymphomaHigh riskLong-term overall survivalDose-intensive chemotherapyRisk-adapted radiotherapyEnd of chemotherapyEvent-free survivalBone marrow involvementPhase III studyRelapse/progressionBest predictive factorChildren's Oncology GroupHigh-risk groupEnhanced risk stratificationTreatment of childrenPET-positive lesionsBulky involvement